Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients

Shu T. Chen, Shyang H. Ferng, Chwei Shiun Yang, Sheng Jeng Peng, Huei Rong Lee, Jiun Rong Chen

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: Hyperlipidemic factors contribute to the high cardiovascular risk in hemodialysis patients. Soy protein has decreased some atherogenic lipid concentrations in subjects with normal renal function. This study evaluates the effect of soy protein on serum lipid profiles in hyperlipidemic and normolipidemic hemodialysis patients. Methods: Nineteen hyperlipidemic and 18 normolipidemic hemodialysis patients were enrolled in a randomized, double-blind, placebo-controlled, clinical trial. After a 4-week run-in phase, subjects in each category were randomly assigned to 2 groups. Thirty grams of isolated soy protein or milk protein was consumed daily as a beverage at breakfast or postdialysis for 12 weeks. Results: In hyperlipidemic subjects, soy protein intake significantly decreased total cholesterol levels by 18.6% (95% confidence interval [CI], -11.4 to -25.8; P = 0.04), triglyceride levels by 43.1% (95% CI, -34.0 to -52.2; P = 0.02), non-high-density lipoprotein cholesterol levels by 23.6% (95% CI, -14.7 to -32.5; P <0.01), apolipoprotein B levels by 15.4% (95% CI, -5.4 to -25.4; P = 0.01), and insulin levels by 49.8% (95% CI, -23.3 to -66.1; P <0.01). Low-density lipoprotein cholesterol concentration was decreased significantly (-25.8%; 95% CI, -8.3 to -42.7; P = 0.01), and high-density lipoprotein cholesterol level was increased significantly (17%; 95% CI, 2 to 32.0; P = 0.03), but there was no significant difference compared with the milk protein group (-5.5% ± 16.9% and 7.0% ± 11.8%, respectively). There were no significant changes in serum lipid and lipoprotein concentrations in normolipidemic subjects. Conclusion: These results indicate soy protein substitution has lipid-lowering effects in hyperlipidemic hemodialysis patients. However, soy protein intake had little effect on plasma lipid levels in normolipidemic hemodialysis patients.

Original languageEnglish
Pages (from-to)1099-1106
Number of pages8
JournalAmerican Journal of Kidney Diseases
Volume46
Issue number6
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Soybean Proteins
Renal Dialysis
Confidence Intervals
Lipids
Milk Proteins
Soy Milk
Breakfast
Beverages
Controlled Clinical Trials
Apolipoproteins B
Serum
LDL Cholesterol
HDL Cholesterol
Lipoproteins
Triglycerides
Cholesterol
Placebos
Insulin
Kidney

Keywords

  • Apolipoprotein
  • Cholesterol
  • Hemodialysis (HD)
  • Lipid
  • Lipoprotein
  • Soy protein
  • Triglyceride

ASJC Scopus subject areas

  • Nephrology

Cite this

Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients. / Chen, Shu T.; Ferng, Shyang H.; Yang, Chwei Shiun; Peng, Sheng Jeng; Lee, Huei Rong; Chen, Jiun Rong.

In: American Journal of Kidney Diseases, Vol. 46, No. 6, 12.2005, p. 1099-1106.

Research output: Contribution to journalArticle

Chen, Shu T. ; Ferng, Shyang H. ; Yang, Chwei Shiun ; Peng, Sheng Jeng ; Lee, Huei Rong ; Chen, Jiun Rong. / Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients. In: American Journal of Kidney Diseases. 2005 ; Vol. 46, No. 6. pp. 1099-1106.
@article{83c54bc906a04e4097abd8638d6cbaa7,
title = "Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients",
abstract = "Background: Hyperlipidemic factors contribute to the high cardiovascular risk in hemodialysis patients. Soy protein has decreased some atherogenic lipid concentrations in subjects with normal renal function. This study evaluates the effect of soy protein on serum lipid profiles in hyperlipidemic and normolipidemic hemodialysis patients. Methods: Nineteen hyperlipidemic and 18 normolipidemic hemodialysis patients were enrolled in a randomized, double-blind, placebo-controlled, clinical trial. After a 4-week run-in phase, subjects in each category were randomly assigned to 2 groups. Thirty grams of isolated soy protein or milk protein was consumed daily as a beverage at breakfast or postdialysis for 12 weeks. Results: In hyperlipidemic subjects, soy protein intake significantly decreased total cholesterol levels by 18.6{\%} (95{\%} confidence interval [CI], -11.4 to -25.8; P = 0.04), triglyceride levels by 43.1{\%} (95{\%} CI, -34.0 to -52.2; P = 0.02), non-high-density lipoprotein cholesterol levels by 23.6{\%} (95{\%} CI, -14.7 to -32.5; P <0.01), apolipoprotein B levels by 15.4{\%} (95{\%} CI, -5.4 to -25.4; P = 0.01), and insulin levels by 49.8{\%} (95{\%} CI, -23.3 to -66.1; P <0.01). Low-density lipoprotein cholesterol concentration was decreased significantly (-25.8{\%}; 95{\%} CI, -8.3 to -42.7; P = 0.01), and high-density lipoprotein cholesterol level was increased significantly (17{\%}; 95{\%} CI, 2 to 32.0; P = 0.03), but there was no significant difference compared with the milk protein group (-5.5{\%} ± 16.9{\%} and 7.0{\%} ± 11.8{\%}, respectively). There were no significant changes in serum lipid and lipoprotein concentrations in normolipidemic subjects. Conclusion: These results indicate soy protein substitution has lipid-lowering effects in hyperlipidemic hemodialysis patients. However, soy protein intake had little effect on plasma lipid levels in normolipidemic hemodialysis patients.",
keywords = "Apolipoprotein, Cholesterol, Hemodialysis (HD), Lipid, Lipoprotein, Soy protein, Triglyceride",
author = "Chen, {Shu T.} and Ferng, {Shyang H.} and Yang, {Chwei Shiun} and Peng, {Sheng Jeng} and Lee, {Huei Rong} and Chen, {Jiun Rong}",
year = "2005",
month = "12",
doi = "10.1053/j.ajkd.2005.08.031",
language = "English",
volume = "46",
pages = "1099--1106",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients

AU - Chen, Shu T.

AU - Ferng, Shyang H.

AU - Yang, Chwei Shiun

AU - Peng, Sheng Jeng

AU - Lee, Huei Rong

AU - Chen, Jiun Rong

PY - 2005/12

Y1 - 2005/12

N2 - Background: Hyperlipidemic factors contribute to the high cardiovascular risk in hemodialysis patients. Soy protein has decreased some atherogenic lipid concentrations in subjects with normal renal function. This study evaluates the effect of soy protein on serum lipid profiles in hyperlipidemic and normolipidemic hemodialysis patients. Methods: Nineteen hyperlipidemic and 18 normolipidemic hemodialysis patients were enrolled in a randomized, double-blind, placebo-controlled, clinical trial. After a 4-week run-in phase, subjects in each category were randomly assigned to 2 groups. Thirty grams of isolated soy protein or milk protein was consumed daily as a beverage at breakfast or postdialysis for 12 weeks. Results: In hyperlipidemic subjects, soy protein intake significantly decreased total cholesterol levels by 18.6% (95% confidence interval [CI], -11.4 to -25.8; P = 0.04), triglyceride levels by 43.1% (95% CI, -34.0 to -52.2; P = 0.02), non-high-density lipoprotein cholesterol levels by 23.6% (95% CI, -14.7 to -32.5; P <0.01), apolipoprotein B levels by 15.4% (95% CI, -5.4 to -25.4; P = 0.01), and insulin levels by 49.8% (95% CI, -23.3 to -66.1; P <0.01). Low-density lipoprotein cholesterol concentration was decreased significantly (-25.8%; 95% CI, -8.3 to -42.7; P = 0.01), and high-density lipoprotein cholesterol level was increased significantly (17%; 95% CI, 2 to 32.0; P = 0.03), but there was no significant difference compared with the milk protein group (-5.5% ± 16.9% and 7.0% ± 11.8%, respectively). There were no significant changes in serum lipid and lipoprotein concentrations in normolipidemic subjects. Conclusion: These results indicate soy protein substitution has lipid-lowering effects in hyperlipidemic hemodialysis patients. However, soy protein intake had little effect on plasma lipid levels in normolipidemic hemodialysis patients.

AB - Background: Hyperlipidemic factors contribute to the high cardiovascular risk in hemodialysis patients. Soy protein has decreased some atherogenic lipid concentrations in subjects with normal renal function. This study evaluates the effect of soy protein on serum lipid profiles in hyperlipidemic and normolipidemic hemodialysis patients. Methods: Nineteen hyperlipidemic and 18 normolipidemic hemodialysis patients were enrolled in a randomized, double-blind, placebo-controlled, clinical trial. After a 4-week run-in phase, subjects in each category were randomly assigned to 2 groups. Thirty grams of isolated soy protein or milk protein was consumed daily as a beverage at breakfast or postdialysis for 12 weeks. Results: In hyperlipidemic subjects, soy protein intake significantly decreased total cholesterol levels by 18.6% (95% confidence interval [CI], -11.4 to -25.8; P = 0.04), triglyceride levels by 43.1% (95% CI, -34.0 to -52.2; P = 0.02), non-high-density lipoprotein cholesterol levels by 23.6% (95% CI, -14.7 to -32.5; P <0.01), apolipoprotein B levels by 15.4% (95% CI, -5.4 to -25.4; P = 0.01), and insulin levels by 49.8% (95% CI, -23.3 to -66.1; P <0.01). Low-density lipoprotein cholesterol concentration was decreased significantly (-25.8%; 95% CI, -8.3 to -42.7; P = 0.01), and high-density lipoprotein cholesterol level was increased significantly (17%; 95% CI, 2 to 32.0; P = 0.03), but there was no significant difference compared with the milk protein group (-5.5% ± 16.9% and 7.0% ± 11.8%, respectively). There were no significant changes in serum lipid and lipoprotein concentrations in normolipidemic subjects. Conclusion: These results indicate soy protein substitution has lipid-lowering effects in hyperlipidemic hemodialysis patients. However, soy protein intake had little effect on plasma lipid levels in normolipidemic hemodialysis patients.

KW - Apolipoprotein

KW - Cholesterol

KW - Hemodialysis (HD)

KW - Lipid

KW - Lipoprotein

KW - Soy protein

KW - Triglyceride

UR - http://www.scopus.com/inward/record.url?scp=28044472771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28044472771&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2005.08.031

DO - 10.1053/j.ajkd.2005.08.031

M3 - Article

C2 - 16310576

AN - SCOPUS:28044472771

VL - 46

SP - 1099

EP - 1106

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 6

ER -